Skip Navigation
Find a Doctor
 
 
 
 

 

Photo of Dr. Samuel Denmeade

Samuel Ray Denmeade, MD

Professor of Oncology

See Research on Pubmed

Male
Appointment Phone

410-955-8964

Main Location

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

View All Locations
Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-0773 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Professor of Oncology
  • Professor of Urology

Centers & Institutes

  • Sidney Kimmel Comprehensive Cancer Center

Expertise

Bladder Cancer, Clinical Trials, Kidney Cancer, Medical Oncology, Prostate Cancer, Testicular Cancer

Research Interests

Targeted Drug Development; Bladder Cancer; Prostate and Renal Cancer; Targeted therapies for cancer; Prodrugs; Protoxins; Protease biology; Protease inhibitors; Cancer imaging

Biography

Dr. Samuel Denmeade is a professor of oncology and urology at the Johns Hopkins School of Medicine. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer.

Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine.

His research interests include prostate and renal cancer, bladder cancer and targeted drug development.

Dr. Denmeade was named the Carolyn and Bill Stutt Scholar by The Patrick C. Walsh Prostate Cancer Research Fund in 2012.

Languages

  • English
  • Spanish

Clinical Trial Keywords

  • kidney cancer
  • bladder cancer
  • prostate cancer
Additional Resources +
  • Education +

    Training

    • Columbia University College of Physicians and Surgeons (New York NY) (1989)

    Residencies

    • The University of Chicago (Chicago IL) (1992)

    Fellowships

    • Johns Hopkins University School of Medicine / Medical Oncology (Baltimore MD) (1998)
    • Johns Hopkins University School of Medicine / Oncology (Baltimore MD) (1996)

    Certifications

    • American Board of Internal Medicine / Medical Oncology (2005)
  • Research & Publications +

    Research Summary

    The main research goals of Dr. Denmeade’s laboratory are: (1) to identify and study the biology of novel cancer selective targets whose enzymatic function can be exploited for therapeutic and diagnostic purposes; (2) to develop methods to target novel agents for activation by these cancer selective targets while avoiding or minimizing systemic toxicity; and (3) to develop novel agents for imaging cancer sites at earliest stages.

    To accomplish these objectives the lab has originally focused on the development of prodrugs or protoxins that are inactive when given systemically via the blood and only become activated by tumor or tissue specific proteases present within sites of tumor.

    Using this approach, Dr. Denmeade and his lab are developing therapies targeted for activation by the serine proteases prostate-specific antigen (PSA), human glandular kallikrein 2 (hK2) and fibroblast activation protein (FAP) as well as the membrane carboxypeptidase prostate-specific membrane antigen (PSMA). One such approach developed in the lab consists of a potent bacterial protoxin that they have reengineered to be selectively activated by PSA within the Prostate. This PSA-activated toxin is currently being tested clinically as treatment for men with recurrent prostate cancer following radiation therapy. In a related approach, a novel peptide-cytotoxin prodrug candidate that is activated by PSMA has been identified and is this prodrug candidate is now entering early phase clinical development. In addition, they have also identified a series of potent inhibitors of PSA that are now under study as drug targeting and imaging agents to be used in the treatment and detection of prostate cancer.

    Selected Publications View all on PubMed

    1. Brandy, Y.; Ononiwu, I.; Adedeji, D.; Williams, V.; Mouamba, C.; Kanaan, Y.; Copeland, R.L., Jr.; Wright, D.A.; Butcher, R.J.; Denmeade, S.R.; Bakare, O. Synthesis and cytotoxic activities of some 2-Arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines. Invest New Drugs. 2011 Jan 18;Epub 1/19/11.
    2. Weiss, M.B.; Vitolo, M.I.; Mohseni, M.; Rosen, D.M.; Denmeade, S.R.; Park, B.H.; Weber, D.J.; Bachman, K.E. Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene. 2010 Aug 19;29(33):4715-4724.
    3. Keizman, D.; Zahurak, M.; Sinibaldi, V.; Carducci, M.; Denmeade, S.; Drake, C.; Pili, R.; Antonarakis, E.S.; Hudock, S.; Eisenberger, M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res. 2010 Nov 1;16(21):5269-5276.
    4. Hu, R.; Denmeade, S.R.; Luo, J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab. 2010 Sep;5(5):753-764.
    5. Denmeade, S.R.; Isaacs, J.T. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate. 2010 Oct 1;70(14):1600-1607.
  • Academic Affiliations & Courses +

    Graduate Program Affiliation

    Chemical and Biomolecular Engineering

  • Activities & Honors +

    Honors

    The Carolyn and Bill Stutt Scholar, the Patrick C. Walsh Prostate Cancer Research Fund, 2012

  • Videos & Media +
  • Events +
  • Contact & Locations +

    Locations

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    401 N. Broadway
    Baltimore, MD 21231
    Appointment Phone: 410-955-8964
    Location Map

    Department/Division

    • Oncology

    For Research Inquiries Contact

    The Bunting-Blaustein Cancer Research Building,
    1650 Orleans Street,
    Baltimore, MD 21231
    Telephone Number: 410-955-8875
    Fax Number: 410-614-8397
    E-mail address: denmesa@jhmi.edu

Is This You? Edit Profile

 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.